

Application No. 10/525,111
Amendment Dated 01/05/2007
Reply to Office Action of 12/07/2006

Remarks/Arguments:

Applicants have provided a corrected section "Amendments to the Specification" wherein line and page numbers from the originally filed (PCT) specification have been used in place of paragraph marks from the published US application.

Applicants would like to draw the Examiners attention to the fact that, because of the differences in layout between the application as filed and the published US application, the above section has had to be altered slightly, however, all the substantive amendments made in our response dated 16 November, 2006 are contained herein and no additional amendments are presented in this response. The changes to the previous amendment, other than those requested by the Examiner, are in presentation only.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100812-1P US.

Respectfully submitted,
/Lucy Padget/

Name: Lucy Padget
Dated: 5th January 2007
Reg. No.: L0074
Phone No.: 781-839-4182
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451